Skip to main content

Table 3 Literature review of liver transplantation for propionic acidemia

From: Therapeutic potential of living donor liver transplantation from heterozygous carrier donors in children with propionic acidemia

References

n

Onset of PA

Indication for LT

Age at LT (years)

Graft type

Follow-up (months)

Post-LT PA-related complications

Post-LT transplant-related complications

Graft survival

Patient survival

Kayler et al. [34]

1

Early

n/a

3

Deceased

0.3

No

N/A

0/1

0/1

Yorifuji et al. [33]

3

Early (n = 3)

PMC (n = 3)

2.2 (1.2–5.1)

Living (n = 3)

2.5 (1.8–4.9)

MD (n = 1)

N/A

3/3

3/3

Manzoni et al. [32]

1

Early

PMC

0.7

Deceased

0.8

No

N/A

1/1

1/1

Romano et al. [31]

1

Late

CM

6.5

Deceased

0.5

No

N/A

1/1

1/1

Amelook et al. [30]

1

Late

CM

16

Deceased

 > 1

No

N/A

1/1

1/1

Kasahara et al. [29]

3

Early (n = 2)

Late (n = 1)

PMC (n = 2)

CM (n = 1)

2 (0.6–2.2)

Living (n = 3)

1.7 (1.4–3.4)

No

CMV (n = 2)

3/3

3/3

Ryu et al. [28]

1

Early

PMC

1.8

Living

0.01

MD (n = 1)

HVO

0/1

0/1

Arrizza et al. [27]

1

Late

CM

22

Deceased

11

No

N/A

1/1

1/1

Charbit-Henrion et al. [15]

12

Early (n = 12)

PMC (n = 8)a

CM (n = 3)a

Preventative (n = 2)

3.2 (1.1–9.0)

Deceased (n = 12)

0.39 (0.01–21)

No

BS (n = 1), HAT (n = 4), Primary nonfunction (n = 13), PTLD (n = 2)

5/17

5/12

Honda et al. [26]

1

Early

PMC

4.0

Living

0.13

No

AMR

0/1

0/1

Silva et al. [25]

2

Early (n = 1)

Late (n = 1)

CM (n = 2)

12.5 and 5.5

Deceased (n = 2)

4 and 5

No

N/A

2/2

2/2

Critelli et al. [23]

2

Early

CM (n = 1)

preventative (n = 1)

8.7 and 1.2

Deceased (n = 2)

2.5 and 1.7

No

ACR (n = 2), CMV (n = 1),

HAT (n = 1)

2/2

2/2

Moguilevitch et al. [24]

1

Early

PMC

4.0

Deceased

2

No

N/A

1/1

1/1

Quintero et al. [14]

6

Early (n = 3)

Late (n = 3)

PMC (n = 4)

Preventative (n = 2)

5.2 (1.3–7.5)

Living (n = 3)

Deceased (n = 3)

1.5 (0.5–4.0)

No

HAT (n = 2)

6/6

6/6

Celik et al. [21]

1

Early

PMC

11.8

Living (unrelated)

2.1

No

HAT (n = 1)

1/1

1/1

Chu et al. [10]

2

n/a

n/a

n/a

n/a

n/a

n/a

N/A

2/2

2/2

Pillai et al. [22]

8

Early

PMC (n = 8)

2.0 (0.4–9.4)

Deceased (n = 8)

5.4 (1.3–17.1)

No

ACR (n = 2), Chronic rejection (n = 1), HAT (n = 1), IVC stenosis (n = 1), Portal vein stenosis (n = 1)

8/9

8/8

Shanmugam et al. [20]

5

Early (n = 1)

late (n = 1)

n/a (n = 3)

PMC (n = 3)

CM (n = 1)

preventative (n = 1)

2.8 (0.7–4.6)

Living (n = 5)

2.8 (1.6–4.2)

MD (n = 1)

HAT (n = 1)

5/5

5/5

Curnock et al. [13]

14

Early (n = 12)

late (n = 1)

n/a (n = 1)

PMC (n = 10)

preventative (n = 4)

2.4 (0.8–7.1)

Living (n = 1)

deceased (n = 13)

4.8 (0.1–22.3)

MD (n = 5)

CM (n = 4)

ACR (n = 6), CMV (n = 6), HAT (n = 1), LCR (n = 2), PTLD (n = 1)

11/16

11/14

Tuchmann-Durand et al. [19]

1

Early

PMC and CM

5

Deceased (n = 1)

0.02

n/a

N/A

1/1

1/1

  1. ACR acute cellular rejection, AMR antibody-mediated rejection, BS biliary sepsis, CM cardiomyopathy, HAT hepatic artery thrombosis, HVO hepatic vein obstruction, LCR late cellular rejection, LT liver transplantation, MD metabolic decompensation, n/a not available, PMC poor metabolic control, PTLD posttransplant lymphoproliferative disease
  2. aThe indication for liver transplantation in one patient was poor metabolic control and cardiomyopathy